IGF-I injection into patellar tendons aims to boost collagen synthesis and improve structure

Patellar tendinopathy, often called "jumper's knee," is a common overuse injury characterized by chronic pain and degeneration of the patellar tendon. It's a challenging condition to treat, with current therapies often failing to fully restore tendon structure and function. The underlying pathology involves disorganized collagen fibers and impaired healing, leading to persistent pain and reduced athletic performance. Insulin-like Growth Factor-I (IGF-I) is a potent anabolic peptide known to stimulate collagen synthesis and cell proliferation, making it a promising candidate for enhancing tendon repair and regeneration.

This randomized, double-blind, basic science study enrolled 15 patients with chronic knee tendon pain. Participants received an ultrasound-guided injection of either Insulin-like Growth Factor-I (IGF-I) or saline (control) into one patellar tendon. The contralateral tendon received the opposite injection. Injections were timed 24 hours and 6 hours before tissue sampling. The primary endpoint was to measure collagen synthesis as fractional synthesis rate, aiming to assess the effect of IGF-I combined with training on tendon structure.

The provided abstract and detailed description focus solely on the study's purpose and methodology, without presenting any results or findings. Therefore, specific data points, statistical outcomes, or quantitative changes in collagen synthesis or tendon structure are not available from this record. The study aimed to test the hypothesis that IGF-I stimulation of new structural tendon proteins, combined with training, would improve tendon structure. However, the outcomes of this investigation are not reported in the provided text.